NEW YORK (GenomeWeb News) – Affymetrix reported after the close of the market Wednesday that its second-quarter revenues declined 6 percent year-over-year while a loss in the year-ago period swung to a $7.3 million profit.

Affy posted total second-quarter revenue of $81.6 million, compared to $86.9 million in the comparable period of 2008. The company reported a negative currency impact of $3 million.

Its results handily beat analysts' consensus estimate of $77.1 million. In early Thursday trade on the Nasdaq, Affy's shares soared 24 percent to $7.28.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.